Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTANYL-50 vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression. It also interacts with kappa and delta receptors to a lesser extent.
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Management of breakthrough pain in cancer patients (opioid-tolerant) (approved for transmucosal formulations),Anesthesia induction and maintenance (IV use),Premedication for anesthetic procedures,Off-label: Severe acute pain in emergency settings (e.g., procedural sedation),Off-label: Chronic pain management (transdermal patch only for opioid-tolerant patients)
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
50 mcg intravenously every 5-10 minutes as needed for breakthrough pain or for induction of anesthesia; for transdermal, 12-100 mcg/hour applied every 72 hours.
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Terminal elimination half-life: 3-12 hours (mean 7 hours); context: prolonged with continuous infusion or in elderly, hepatic impairment, or obesity due to accumulation in adipose tissue.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Primarily metabolized via CYP3A4 in the liver to norfentanyl (inactive) and other metabolites; minor contributions from CYP3A5. Less than 10% excreted unchanged in urine.
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Renal: 75% (primarily as metabolites, <10% unchanged); Fecal: 9%; Biliary: minor contribution.
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
80-85% bound, primarily to alpha-1-acid glycoprotein and albumin.
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
3-8 L/kg (mean 4 L/kg); high Vd indicates extensive distribution into tissues including skeletal muscle and fat.
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
IV: 100%; Transdermal: 92% (relative to IV, absolute bioavailability ~92%); Transmucosal (buccal, sublingual): 50-70%; Intranasal: 70-90%; Oral: low (<50% due to first-pass metabolism).
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
GFR 30-60 m L/min: reduce dose by 25-50%; GFR <30 m L/min: avoid or reduce dose by 50-75% and monitor closely.
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75% or avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Intravenous: 0.5-2 mcg/kg per dose every 5-10 minutes as needed; transdermal: not recommended for children under 2 years; for children >2 years, start at 12 mcg/hour based on prior opioid exposure.
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Starting dose should be 50-75% lower than in younger adults; titrate slowly; transdermal patch starting dose no higher than 25 mcg/hour; monitor for respiratory depression and cognitive impairment.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Black Box Warning: Risk of respiratory depression, addiction, abuse, and misuse; life-threatening respiratory depression and death can occur at any dose, especially with initial use or dose escalation. Concomitant use with CNS depressants (e.g., benzodiazepines, alcohol) may cause profound sedation, respiratory depression, coma, and death. Accidental exposure (especially in children) can be fatal.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
Risk of respiratory depression requires monitoring; use with caution in COPD, decreased respiratory reserve, or hypoxia,Serotonin syndrome risk with concomitant serotonergic drugs,Adrenal insufficiency and androgen deficiency with prolonged use,Neonatal opioid withdrawal syndrome with prolonged maternal use during pregnancy,Severe hypotension, especially in hypovolemic patients,QT prolongation (high doses, especially IV),Risks of tolerance, physical dependence, and withdrawal upon abrupt discontinuation
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Hypersensitivity to fentanyl or any component,Acute or severe bronchial asthma in unmonitored settings,Significant respiratory depression (without resuscitative equipment),Paralytic ileus or known gastrointestinal obstruction,Concurrent use with MAOIs (within 14 days) for immediate-release forms (dose adjustment may be considered for transdermal under strict monitoring)
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
Avoid alcohol; concurrent use increases risk of CNS depression and respiratory arrest. No specific food interactions; maintain usual diet. Grapefruit juice may slightly increase fentanyl levels via CYP3A4 inhibition but clinical significance is minimal with transdermal route.
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
First trimester: Limited data, but animal studies show no structural teratogenicity at clinically relevant doses. Second/third trimester: Chronic exposure may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at delivery. Avoid prolonged use.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
Fentanyl is excreted in breast milk in low amounts (M/P ratio ~0.4-0.5). Single doses are unlikely to harm infant, but chronic use may cause sedation or respiratory depression in the neonate. Monitor for drowsiness, poor feeding. Benefit-risk assessment recommended.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
Pregnancy may increase clearance of fentanyl due to expanded plasma volume and enhanced hepatic metabolism. Higher doses may be required for adequate analgesia, especially in the third trimester. Postpartum dose reduction may be needed. Individualize based on response and adverse effects.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
Fentanyl 50 mcg/hr patch provides continuous systemic opioid delivery. Onset of action 12-24 hours; steady state in 72 hours. Do not cut or use damaged patches. Avoid heat sources (fever, heating pads, saunas) as they increase absorption and risk of overdose. Monitor for respiratory depression, especially in opioid-naïve patients. C max may increase by 25-40% with fever. Apply to non-irritated, non-hairy skin on upper torso. Use in opioid-tolerant patients only.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
Apply patch to clean, dry, hairless skin on chest or back, avoiding scars, lesions, or irritated skin.,Do not cut, tear, or alter the patch in any way; this can cause rapid, fatal drug absorption.,Wash hands after applying or removing patch; avoid touching eyes or mucous membranes.,Keep away from children and pets; used patches should be folded, placed in original packaging, and disposed of per local drug take-back programs.,Avoid hot tubs, saunas, electric blankets, heating pads, or prolonged sun exposure while wearing patch; fever can increase absorption.,Do not drink alcohol while using fentanyl; it can cause severe drowsiness, respiratory depression, and death.,Common side effects include nausea, constipation, drowsiness, and dizziness. Contact healthcare provider if you experience confusion, slow or shallow breathing, or severe sedation.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
"Metaraminol, a direct-acting alpha-adrenergic agonist, can reduce the serum concentration of fentanyl, a potent opioid analgesic, likely through enhanced hepatic metabolism or altered renal clearance. This interaction may lead to diminished analgesic efficacy of fentanyl, requiring higher doses to achieve pain control and potentially increasing the risk of opioid withdrawal symptoms. Clinically, patients receiving both drugs may exhibit inadequate pain relief or unexpected opioid tolerance."
"The concomitant use of pergolide, a dopamine receptor agonist, and fentanyl, a μ-opioid receptor agonist, may result in additive central nervous system depression, leading to increased sedation, respiratory depression, and potential for coma or death. Pergolide can also potentiate the hypotensive effects of opioids, resulting in orthostatic hypotension and syncope. Additionally, both drugs can prolong the QTc interval, increasing the risk of torsades de pointes and sudden cardiac death."
"The combination of glycopyrronium, an anticholinergic agent, and fentanyl, a potent mu-opioid receptor agonist, can result in additive anticholinergic effects, specifically severe constipation, urinary retention, and central nervous system depression, leading to delirium or cognitive impairment in susceptible patients. Additionally, fentanyl-induced gastrointestinal hypomotility is exacerbated by glycopyrronium, increasing the risk of paralytic ileus. Clinically, patients may present with prolonged QTc interval, decreased gastrointestinal motility, and exacerbated sedation, particularly in elderly or renally impaired individuals."
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTANYL-50 vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE, answered by our medical review team.
FENTANYL-50 is a Opioid Agonist that works by Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression. It also interacts with kappa and delta receptors to a lesser extent.. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTANYL-50 and ACETAMINOPHEN AND HYDROCODONE BITARTRATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTANYL-50 is: 50 mcg intravenously every 5-10 minutes as needed for breakthrough pain or for induction of anesthesia; for transdermal, 12-100 mcg/hour applied every 72 hours.. The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining FENTANYL-50 and ACETAMINOPHEN AND HYDROCODONE BITARTRATE. Hydrocodone and fentanyl are both opioid agonists that activate mu-opioid receptors in the central nervous system, producing additive analgesic and central nervous system (CNS) depressant effects. This synergistic pharmacodynamic interaction increases the risk of profound sedation, respiratory depression, coma, and death. Concurrent use is particularly dangerous in opioid-naïve patients or those with compromised respiratory function, and the combination should be avoided or used only under strict supervision for severe pain unresponsive to monotherapy. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. FENTANYL-50 is classified as Category D/X. First trimester: Limited data, but animal studies show no structural teratogenicity at clinically relevant doses. Second/third trimester: Chronic exposure may cause neonatal opioid. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.